IBI354 Clinical Trials

3 actively recruiting trials

Pipeline

Phase 3: 2Phase 1/2: 1

Top Sponsors

Innovent Biologics (Suzhou) Co. Ltd.2
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.1

Indications

Cancer3
Ovarian1
Primary Peritoneal1
Locally Advanced (Unresectable) or Metastatic Solid Tumors1
Fallopian Tube Cancer1

Other3 trials

A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors

Phase 1/2

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

Phase 3

Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.